262 18 MONTHS FOLLOWUP AFTER INTRA-ARTICULAR ADMINISTRATION OF HYALUBRIX® IN 344 PATIENTS WITH SYMPTOMATIC OSTEOARTHRITIS OF THE HIP  by Migliore, A. et al.
S118 Osteoarthritis and Cartilage Vol. 16 Supplement 4
the incidence of bursitis “pes anserinum” in patients with OA of knee
joints, its association with ﬂat-foot and the inﬂuence of complex treatment
with the use of insoles during disease’s course.
Methods: Patients consulted a rheumatologist on the occasion of wors-
ening the course of the disease. 52 patients with OA of knee joints
were examined. All patients were administered clinical and instrumental
examinations which included objective examination, full blood count,
urinalysis, blood serum creatinine, serum glutamic transaminase, serum
asparagines transaminase, the X-ray of knee joints, the ultrasonic exam-
ination of knee joints and periarticular tissues using the Sonoline G 50
device.
Results: The initial examination showed that most patients – 43 (82%)
had had a chronic recurrent course of the disease that had made them
take non-steroid anti-inﬂammatory medicines and use ointments. X-ray
stage I of the disease (Kellgren and Lawrence, 1957) was diagnosed in
10 (19%) patients, stage II and stage III – in 26 (50%) and 16 (31%)
patients respectively. Women (mean age 63) constituted 85% of the
whole patient’s group. The given proportion of women corresponded to
the epidemiological ﬁndings. On the average, all patients had a 6-year
history of the disease. Swelling of knee joints, tenderness along the
articular space and the periarticular area on the medial side were revealed
on palpation. The activity of the disease was evaluated by the patients
according to 100mm visual analogue scale (VAS). It was assessed by
the rheumatologist by the same scale. Pain at rest, pain during motion,
the quality of life were estimated by means of the questionnaire (HAG).
Bursitis “pes anserinum” was revealed in 22 (42%) patients, mainly with
stage II of knee joints’ OA and conﬁrmed by the ultrasonic examination of
the joints. Women’s mean age in this group was 66 years, all women were
overweighed. The diagnosis of combined (mainly longitudinal) stage I and
stage II ﬂat-foot in these patients was conﬁrmed by stereoplantopodog-
raphy and aroused their great interest invariably. When being asked the
patients said that they had experienced pain in their feet and tiredness of
their legs by the end of the day. The patients considered it to be natural
phenomenon which did not require any treatment. Complex non-medical
treatment included individual approach to every patient, wearing insoles
to correct ﬂat-foot, which enabled to improve the functional activity of
their knee joints, and was noted by the patients. Medical therapy was
identical for all patients and consisted of a non-steroid anti-inﬂammatory
medicine, intrajoint corticosteroids according to indications, periarticular
corticosteroids in the area of “pes anserinum”, physiotherapeutic treat-
ment (magnet therapy) and a symptomatic medicine of a slow action.
The received ﬁndings demonstrated a decrease of pain by 61mm (VAS)
and an improvement of the life quality by 4.7 points 10 days after the
treatment.
Conclusions: The correction of ﬂat-foot by means of knee joints’ OA
complex treatment enables to reduce the overload on the medial group of
femoral muscles and to stabilize the shin that abates the disease activity
and prolongs a stable course of the disease. The received ﬁndings have
revealed a low level of knowledge about ﬂat-foot as about a problem
which inﬂuences the normal functioning of feet and knee joints.
261 METABOLIC SYNDROME AND THE INCIDENCE OF
DEEP VEIN THROMBOSIS FOLLOWING TOTAL KNEE
ARTHROPLASTY
R. Gandhi. University of Toronto, Toronto, ON, CANADA
Purpose:We asked if patients with metabolic syndrome (MS) undergoing
total knee arthroplasty (TKA) have an increased risk for symptomatic
deep vein thrombosis (DVT).
Methods: We surveyed 1460 consecutive patients undergoing primary
TKA for relevant covariates. Metabolic syndrome was deﬁned as body
mass index above 30 kg/m2, diabetes, hypertension, and hypercholes-
terolemia.
Results: The overall incidence of symptomatic DVT was 4.4% (65/1460).
Patients with MS had an increased incidence of DVT as compared
to those without MS (15.5% vs 3.4%). Adjusted analysis showed that
MS increased the risk of symptomatic DVT by 4.2 (95% CI [1.5, 11.4],
p = 0.006) times compared to those without MS.
Conclusions: Protocols developed for prophylactic anti-coagulation
should give consideration to patients with metabolic syndrome.
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Purpose: Investigation into the long term duration of beneﬁt after
ultrasound-guided intra-articular injection of Hyalubrix ® in patient with
hip OA.
Background: HYAP15 (Hyalubrix®) is a sterile, non pyrogenic, viscoelas-
tic solution manufactured with hyaluronic acid sodium salt for intra-
articular injection, obtained by bacterial fermentation from fraction of
high molecular weight (>1500 kDa) having Sodium hyaluronate 15mg/ml.
Hyalubrix® is marketed in Italy, Austria and Germany for the treatment of
degenerative or mechanical arthropathy and it is mainly used for the treat-
ment of the knee OA patients. A post marketing study on 1523 patients
affected by knee or hip OA supported the efﬁcacy and safety behaviour
of Hyalubrix® in pain reduction and functionality improvement. Literature
data regarding hip joint viscosupplementation are at now still limited to
small studies. We previously performed a comparative study for Hyalubrix
vs Carbocaine with a follow up of six months with good results in terms
of efﬁcacy and safety for Hyalubrix. Neverthless, at now there are no post
marketing cohort studies on hyalubrix in hip OA.
Methods: 344 adults, ambulatory patients suffering from hip OA grade 1
to 3 according to Kellgren and Lawrence were considered eligible for
the study. Patients were injected with two syringes (4ml) of Hyalubrix,
repeated every six month, and in some cases, if clinically requested, every
three months, under ultrasound guidance. A 3.5MHz convex transducer
was used with a sterilised biopsy guide attached. The hip joint was
scanned by means of an anterior parasagittal approach. The efﬁcacy
of the injection was assessed by using the Lequesne index and VAS pain
score at baseline and, then, every three months after the ﬁrst injection.
NSAIDs consumption was also evaluated during the month before the
injection and, then, every three months after ﬁrst the injection of Hylubrix
until to 18 months. Safety was assessed by recording any adverse event
during the follow up period.
Efﬁcacy of IA US-guided Hip injection of Hyalubrix® in OA affected
patients.
Table 1 Variations of the assessment criteria after repeated IA injections of Hyalubrix.
Baseline
(N=344)
3 months
(N=256)
6 months
(N=212)
9 months
(N=168)
12 months
(N=149)
15 months
(N=129)
18 months
(N=119)
OA pain VAS 5.8 4.3* 4.2* 4.1* 4.2* 4.1* 4.3*
NSAID
consumption
(Days/month)
6.7 4.4* 2.9* 3.2* 3.6* 3.8* 3.6*
Lequesne
index
7.5 5.6* 4.9* 5.0* 5.5* 5.6* 5.6*
*p< 0.01.
Results: 344 patients were treated, 166M and 177F. 32 had bilateral hip
OA. 8 patients left the study to undergo to hip replacement. 97 patients
are lost to follow up. No local or systemic adverse events were reported.
A statistically signiﬁcant reduction was observed at all time points versus
baseline for all assessment criteria, p< 0.01 (Tab. 1 and Fig. 1).
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Conclusions: Continuous intra-articular use of Hyalubrix in hip OA
affected patients showed to be effective even in the long-term. This
study shows how even at 18 months the use of Hyalubrix is effective in
maintaining the positive effects obtained after the very ﬁrst injection. This
has not only direct positive consequences, as the reduction in NSAID
consumption may also reduce the costs associated with managing the
disease and the costs associated with side-effects induced by NSAIDs.
263 A PATHOMECHANICAL STUDY OF POST-TRAUMATIC
OSTEOARTHRITIS: LINKING INTRA-ARTICULAR FRACTURE
INCONGRUITY TO CARTILAGE DEGENERATION
T.P. Thomas, D.D. Anderson, C.J. van Hofwegen, T.D. Brown,
J.L. Marsh. University of Iowa, Iowa City, IA, USA
Purpose: Residual incongruities following intra-articular fractures have
been associated with aberrant articular contact stress distributions, linked
indirectly to the onset of post-traumatic osteoarthritis (OA). The purpose
of this study was to improve current understanding of the relationship
between patterns of abnormal contact stress exposure and of cartilage
degeneration, using advanced image analysis techniques and patient-
speciﬁc ﬁnite element (FE) modeling.
Methods: Articular joint contact stresses following surgical fracture re-
duction were quantiﬁed using a validated patient-speciﬁc contact ﬁnite
element (FE) analysis. FE models were created from post-reduction CT
studies in a series of 11 tibial plafond fracture patients, including both
the fractured ankles and their intact contralaterals. The chronic contact
stress exposure over a simulated gait cycle was calculated as a metric
of degeneration propensity.
Cartilage outcome was evaluated from dual contrast multi-detector CTs
obtained six months and two years post injury, for six patients. The
contrast agent injected into the joints enabled segmentation of the sub-
chondral bone and cartilage surfaces by a senior orthopaedic resident.
Cartilage thickness was then calculated across the articulating surface
using purpose-written MATLAB code.
Registration of the post-op FE simulations to the two year cartilage
thickness maps was necessary for spatial comparison (performed using
Geomagic Studio software). This was accomplished by using metallic
screws implanted during surgical reduction as ﬁducial markers. The
registered cartilage thickness maps were quantitatively compared to the
FE-computed contact stress exposures.
Figure 1. These inferior views of a fractured tibia’s articular surface
illustrate the FE results (top) and cartilage thickness map (bottom).
Spatial registration enabled pixel-by-pixel correlation between contact
stress exposure and cartilage degeneration.
Results: Localized areas of cartilage thinning generally corresponded to
areas exposed to elevated contact stresses. Contact stress exposures of
2MPa-s or greater were associated with a focal loss of cartilage [Fig 2].
For these six patients, the percent reduction in cartilage volumes from
a pre-fractured state ranged from 11 to 81%. The most severely com-
minuted fractures experienced the greatest loss of cartilage, in addition
to having the greatest contact stresses as assessed by FE. The area of
cartilage loss ranged from 0 to 241mm2.
Conclusions: Clinical experience has shown that residual articular incon-
gruity is poorly tolerated and is a likely factor in the progression of joint
degeneration. FE modeling coupled with advanced imaging analysis tech-
niques is improving our understanding of the mechanopathology of PTOA.
The results from this study support an association between elevated
contact stress exposure and focal cartilage degeneration. No conclusive
statements relating aberrant contact stresses to cartilage thinning can yet
be made from the limited number of patients included. However, there is
a clear spatial connection between large stress exposures over small and
large regions, and focal areas with cartilage degeneration for this series
of patients. Restoration of normal subchondral anatomy may decrease
cartilage loss and slow the development of post-traumatic osteoarthritis.
Financial support was provided by grants from the National Institutes of
Health (AR46601, AR55533, and AR48939), The AO Research Fund and
The Orthopaedic Trauma Association.
Figure 2. Point-by-point comparisons between computed contact stress
exposure and cartilage thickness measures were made over the loaded
articular surface. Cartilage Thickness decreases as the exposure exceeds
2MPa-s.
264 CLINICAL AND RADIOGRAPHIC DETERMINANTS OF
RESPONSIVENESS TO INTRA-ARTICULAR HYALURONAN
INJECTION FOR KNEE OSTEOARTHRITIS
K. Briem, M.J. Axe, L. Snyder-Mackler. University of Delaware, Newark,
DE, USA
Purpose: Intra-articular (IA) injections of hyaluronic acid (HA) have been
shown to improve self-report measures in patients with knee osteoarthritis
(OA). Effects of HA injection on functional outcome measures for this
patient group is not well known and clinical experience leads us to
believe that not everyone beneﬁts from this treatment. Therefore, the
purpose of this study was to study the effects of HA injections on self-
report and functional measures in patients with knee OA and to identify
clinical and/or radiographic characteristics of those likely to respond to
HA injections.
Methods: Forty-eight subjects were recruited and tested prior to, and
no later than 3 weeks following the last of 5 weekly injections. Knee
function was assessed with knee speciﬁc questionnaires (Knee Outcome
Survey (KOS) and Knee OA Outcome Score (KOOS)), a six minute walk
(6MW), a stair climbing task (SCT), as well as knee range of motion
(ROM) and Quadriceps strength measures. A set of ‘a priori’ deﬁned
criteria were used to identify responders (R) and non-responders (NR).
Available radiographs were graded by a single physician according to the
Kellgren-Lawrence (KL) scale.
Results: On average, self-report scores improved signiﬁcantly following
treatment, as did measures for the SMW and SCT, ROM and muscle
performance. Twenty subjects were classiﬁed as non-responders (NR),
whereas 28 subjects, responders (R), improved markedly. Not only did
R improve in self reported function, but in muscle performance, knee
ROM, 6MW and SCT tests, whereas NR gained distance walked during
the 6MW. Furthermore, R consistently improved performance of both the
6MW and the SCT, while the correlation did not hold true in the NR group.
